Drug Profile
MDR 1339
Alternative Names: DBT-1339; MDR-1339Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Medifron DBT
- Developer Daewoong Pharmaceutical; Medifron DBT
- Class Antidementias
- Mechanism of Action Peptide aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease in South Korea
- 28 Aug 2019 MDR 1339 is still in phase I trials for Alzheimer's disease in South Korea (Medifron pipeline, August 2019)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Alzheimer's-disease in South Korea